Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in Ohio: - Summa Health System - Akron Campus — Akron, Ohio
- Aultman Alliance Community Hospital — Alliance, Ohio
- Summa Health System - Barberton Campus — Barberton, Ohio
- Indu and Raj Soin Medical Center — Beavercreek, Ohio
- Saint Elizabeth Boardman Hospital — Boardman, Ohio
Phase 3 Recruiting Academic/Other
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…
Sponsor: NRG Oncology
NCT ID: NCT04852887
Sites in Ohio: - Summa Health System - Akron Campus — Akron, Ohio
- Cleveland Clinic Akron General — Akron, Ohio
- UH Seidman Cancer Center at UH Avon Health Center — Avon, Ohio
- Summa Health System - Barberton Campus — Barberton, Ohio
- UHHS-Chagrin Highlands Medical Center — Beachwood, Ohio
Phase 3 Recruiting Academic/Other
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in Ohio: - Aultman Alliance Community Hospital — Alliance, Ohio
- Aultman Health Foundation — Canton, Ohio
- Miami Valley Hospital South — Centerville, Ohio
- University of Cincinnati Cancer Center-UC Medical Center — Cincinnati, Ohio
- Good Samaritan Hospital - Cincinnati — Cincinnati, Ohio
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Ohio: - UH Seidman Cancer Center at UH Avon Health Center — Avon, Ohio
- Indu and Raj Soin Medical Center — Beavercreek, Ohio
- University of Cincinnati Cancer Center-UC Medical Center — Cincinnati, Ohio
- Case Western Reserve University — Cleveland, Ohio
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Phase 3 Recruiting Industry
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which inc…
Sponsor: Gilead Sciences
NCT ID: NCT05633654
Sites in Ohio: - Good Samaritan Hospital — Cincinnati, Ohio
- Oncology Hematology Care, Inc. — Cincinnati, Ohio
- Ohio State University CRS — Columbus, Ohio
- Ohio Health Research Institute — Columbus, Ohio
- Columbus NCORP — Columbus, Ohio
Phase 3 Recruiting Industry
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early b…
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT06492616
Sites in Ohio: - Miami Valley Hospital South — Centerville, Ohio
- MetroHealth — Cleveland, Ohio
- Cleveland Clinic — Cleveland, Ohio
- Oncology_Hematology Care Clinical Trials, LLC — Fairfield, Ohio
Phase 3 Recruiting Industry
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizuma…
Sponsor: AstraZeneca
NCT ID: NCT06103864
Sites in Ohio: - Research Site — Cincinnati, Ohio
- Research Site — Cincinnati, Ohio
- Research Site — Cleveland, Ohio
Phase 3 Recruiting Industry
This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribo…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06065748
Sites in Ohio: - Oncology Hematology Care — Cincinnati, Ohio
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in th…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06966700
Sites in Ohio: - Good Samaritan Hospital-TriHealth Cancer institute ( Site 0027) — Cincinnati, Ohio
Phase 3 Recruiting Industry
This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participant…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06790693
Sites in Ohio: - Fairview Hospital — Cleveland, Ohio
- Cleveland Clinic Foundation — Cleveland, Ohio
- Hillcrest Hospital — Mayfield Heights, Ohio
Phase 3 Recruiting Academic/Other
This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…
Sponsor: NRG Oncology
NCT ID: NCT06500481
Sites in Ohio: - Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Phase 3 Recruiting Industry
This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have complete…
Sponsor: Greenwich LifeSciences, Inc.
NCT ID: NCT05232916
Sites in Ohio: - Oncology Hematology Care — Cincinnati, Ohio
Phase 3 Recruiting Industry
The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metasta…
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06435429
Sites in Ohio: - Oncology Hematology Care (OHC) — Cincinnati, Ohio
- University Hospitals Cleveland Medical Center 11100 Euclid Ave — Cleveland, Ohio
Phase 3 Recruiting Industry
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who ha…
Sponsor: LeonaBio
NCT ID: NCT05696626
Sites in Ohio: - University Hospitals Seidman Cancer Center — Cleveland, Ohio
- Cleveland Clinic — Cleveland, Ohio
- The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solovev Research Institute (OSUCCC - James) — Columbus, Ohio
Phase 3 Recruiting Industry
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib and palbociclib plus endocrine therapy for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast …
Sponsor: Celcuity Inc
NCT ID: NCT06757634
Sites in Ohio: - Stefanie Spielman Comprehensive Breast Center at Olentangy River Road — Columbus, Ohio
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Ohio: - OhioHealth O'Bleness Hospital — Athens, Ohio
- UH Seidman Cancer Center at UH Avon Health Center — Avon, Ohio
- UHHS-Chagrin Highlands Medical Center — Beachwood, Ohio
- Strecker Cancer Center-Belpre — Belpre, Ohio
- Aultman Health Foundation — Canton, Ohio
Phase 2 Recruiting Industry
PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) …
Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06369285
Sites in Ohio: - The Ohio State University, Stefanie Spielman Comprehensive Breast Center — Columbus, Ohio
- Taylor Cancer Research Center — Maumee, Ohio
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in Ohio: - Gabrail Cancer Center — Canton, Ohio
Phase 2 Recruiting Academic/Other
This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.
Sponsor: Oana Danciu
NCT ID: NCT05467891
Sites in Ohio: - Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Phase 1, Phase 2 Recruiting Industry
This study, the first clinical trial of AVZO-023, aims to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-023 in patients with advanced solid tumors. AVZO-…
Sponsor: Avenzo Therapeutics, Inc.
NCT ID: NCT06998407
Sites in Ohio: - Avenzo Therapeutics Recruiting Site — Cleveland, Ohio
- Avenzo Therapeutics Recruiting Site — Columbus, Ohio
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.
Sponsor: Volastra Therapeutics, Inc.
NCT ID: NCT05902988
Sites in Ohio: - The Christ Hospital — Cincinnati, Ohio
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1b/2, Open-label Study to Investigate the Safety and Efficacy of Invikafusp alfa (STAR0602), a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Combination with Sacituzumab Govitecan in P…
Sponsor: Marengo Therapeutics, Inc.
NCT ID: NCT06827613
Sites in Ohio: - Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd…
Sponsor: GI Innovation, Inc.
NCT ID: NCT05824975
Sites in Ohio: - Cleveland Clinic — Cleveland, Ohio
Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if using a liver-directed therapy with high dose chemotherapy followed by approved cancer treatment to treat patients with breast cancer that has spread to the liver is safe and tolerable. The cl…
Sponsor: Delcath Systems Inc.
NCT ID: NCT06875128
Sites in Ohio: - Cleveland Clinic — Cleveland, Ohio
- Ohio State University, Stefanie Spielman Comprehensive Breast Center — Columbus, Ohio
Phase 2 Recruiting NIH
This phase IIA trial compares the effect of acolbifene versus low dose tamoxifen in preventing breast cancer in premenopausal women at high risk for developing breast cancer. The usual approach for patients at increased risk for breast can…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05941520
Sites in Ohio: - Ohio State University Comprehensive Cancer Center — Columbus, Ohio